We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

179 hedge funds and large institutions have $867M invested in Vanda Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 60 increasing their positions, 72 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 12

23% more capital invested

Capital invested by funds: $704M → $867M (+$164M)

7% more funds holding

Funds holding: 168 → 179 (+11)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.32% less ownership

Funds ownership: 99.45% → 99.13% (-0.32%)

17% less repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 72

79% less call options, than puts

Call options by funds: $738K | Put options by funds: $3.55M

Holders
179
Holders Change
+11
Holders Change %
+6.55%
% of All Funds
3.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
28
Increased
60
Reduced
72
Closed
12
Calls
$738K
Puts
$3.55M
Net Calls
-$2.81M
Net Calls Change
-$1.93M

Top Buyers

Rank Fund Capital Flow
1
WG
Winton Group
United Kingdom
+$8.01M
2
Prudential Financial
Prudential Financial
New Jersey
+$4.71M
3
Macquarie Group
Macquarie Group
Australia
+$4.64M
4
BlackRock
BlackRock
New York
+$4.63M
5
EA
Emerald Advisers
Pennsylvania
+$3.91M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$10.9M
2
Millennium Management
Millennium Management
New York
-$6.78M
3
Federated Hermes
Federated Hermes
Pennsylvania
-$5.49M
4
State Street
State Street
Massachusetts
-$5.02M
5
Goldman Sachs
Goldman Sachs
New York
-$4.65M
Name Holding Trade Value Shares
Change 		Change in
Stake
TFO
176
Tarbox Family Office
California
$1K +$801 +53 New
OPS
177
Orion Portfolio Solutions
Nebraska
$1K +$953 +63 New
Point72 Asset Management
178
Point72 Asset Management
Connecticut
– -$2.97M -223,375 Closed
ARTA
179
A.R.T. Advisors
New York
– -$562K -42,297 Closed
TI
180
Trexquant Investment
Connecticut
– -$396K -29,800 Closed
EGM
181
Engineers Gate Manager
New York
– -$327K -24,609 Closed
ZCM
182
Zebra Capital Management
Connecticut
– -$208K -15,634 Closed
QT
183
Quantamental Technologies
New York
– -$146K -11,013 Closed
CA
184
Calton & Associates
Florida
– -$145K -10,924 Closed
HC
185
Henshaw Capital
Massachusetts
– -$140K -10,572 Closed
Voloridge Investment Management
186
Voloridge Investment Management
Florida
– -$138K -10,368 Closed
DekaBank Deutsche Girozentrale
187
DekaBank Deutsche Girozentrale
Germany
– -$117K -8,600 Closed
TC
188
Trust Company
Kansas
– -$3K -250 Closed
Bessemer Group
189
Bessemer Group
New Jersey
– -$1K -75 Closed
SPIA
190
Steward Partners Investment Advisory
New York
– -$15 -1 -50%
4 5 6 7
8

VNDA Hedge Fund Activity: Q4 2019 in Review

179 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2019, worth a combined $867M — up 23% from $704M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VNDA positions and 12 closed out — a net gain of 16 holders — while 60 added to existing stakes and 72 trimmed.

The largest buyer was Winton Group, adding an estimated $8.01M. The largest seller was Armistice Capital, cutting an estimated $10.9M.

  • 179 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2019, up from 168 in Q3 2019.
  • Funds reported $867M of Vanda Pharmaceuticals stock for Q4 2019, up 23% quarter-over-quarter.
  • 28 funds opened new Vanda Pharmaceuticals positions in Q4 2019 and 12 closed out, a net change of +16 holders.
  • The largest Vanda Pharmaceuticals buyer in Q4 2019 was Winton Group, an estimated $8.01M added.
  • The largest Vanda Pharmaceuticals seller in Q4 2019 was Armistice Capital, an estimated $10.9M sold.

Based on aggregated 13F filings for Q4 2019.